# A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

> **NCT05605522** · PHASE1 · TERMINATED · sponsor: **3B Pharmaceuticals GmbH** · enrollment: 19 (actual)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma (PDAC)
- Squamous Cell Carcinoma of Head and Neck
- Colorectal Cancer
- Gastric Cancer
- Ewing Sarcoma
- NTSR1 Expressing Solid Tumours
- Neuroendocrine Differentiated (NED) Prostate Cancer

## Interventions

- **DRUG:** [225]-FPI-2059
- **DRUG:** [111In]-FPI-2058

## Key facts

- **NCT ID:** NCT05605522
- **Lead sponsor:** 3B Pharmaceuticals GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-02-07
- **Primary completion:** 2024-07-19
- **Final completion:** 2025-02-20
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Sponsor reprioritization of active trials.
- **Last updated:** 2025-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05605522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05605522, "A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05605522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*